The development of monoclonal antibodies for the therapy of cancer
RA Farah, B Clinchy, L Herrera… - Critical Reviews™ in …, 1998 - dl.begellhouse.com
Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only
did this discovery lead to a Nobel prize, but it created an enormous scientific field that has …
did this discovery lead to a Nobel prize, but it created an enormous scientific field that has …
Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity
M Kuroki, K Hachimine, J Huang… - Anticancer …, 2005 - ar.iiarjournals.org
Cellular immunity, in which cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are
main effector cells, plays an important role in the antitumor defense mechanism. T cell …
main effector cells, plays an important role in the antitumor defense mechanism. T cell …
Engineering high affinity superantigens by phage display
C Enever, IM Tomlinson, J Lund, M Levens… - Journal of molecular …, 2005 - Elsevier
Protein L (PpL) is a B-cell superantigen from Peptostreptococcus magnus known to bind to
mammalian Vκ light chains. PpL from P. magnus strain 312 comprises five homologous …
mammalian Vκ light chains. PpL from P. magnus strain 312 comprises five homologous …
Materials and methods for treating oncological disease
MJP Lawman, P Lawman - US Patent 7,094,603, 2006 - Google Patents
Novel methods are disclosed for treating oncological disor ders in an individual or animal
using a Superantigen expressed in tumor cells. A gene encoding a Superantigen, Such as …
using a Superantigen expressed in tumor cells. A gene encoding a Superantigen, Such as …
Antigen modified cancer cell vaccines for cancer therapy
MJP Lawman, PD Lawman - US Patent 7,348,015, 2008 - Google Patents
Disclosed are methods for treating cancers, particularly tumorigenic types. Cancer cells are
modified to express highly immunogenic antigens so that the cells will generate a defensive …
modified to express highly immunogenic antigens so that the cells will generate a defensive …
Tumor cell vaccines
MJP Lawman, P Lawman - US Patent 7,795,020, 2010 - Google Patents
Related US Application Data Continuation-in-part of application No. 10/964,471, filed on
Oct. 13, 2004, now Pat. No. 7,348,015, which is a continuation-in-part of application No …
Oct. 13, 2004, now Pat. No. 7,348,015, which is a continuation-in-part of application No …
Cancer-homing toxins
HC Ng, HE Khoo - Current pharmaceutical design, 2002 - ingentaconnect.com
Cancer-homing toxins are a group of man-made cytotoxic molecules targeting cancer cells.
In the past decade they have demonstrated potential as cancer therapeutics. These …
In the past decade they have demonstrated potential as cancer therapeutics. These …
[HTML][HTML] Disulfide-stabilized single-chain antibody-targeted superantigen: Construction of a prokaryotic expression system and its functional analysis
JL Wang, YL Zheng, R Ma, BL Wang… - World Journal of …, 2005 - ncbi.nlm.nih.gov
AIM: To construct the expression vector of B3 (scdsFv)-SEA (D227A) and to identify its
binding and cytotoxic ability to B3 antigen positive carcinoma cell lines. METHODS: This …
binding and cytotoxic ability to B3 antigen positive carcinoma cell lines. METHODS: This …